B+L gains option to acquire joint venture Technolas
This article was originally published in Clinica
Bausch + Lomb now has the option to purchase in full its joint venture, Technolas Perfect Vision (TPV), which it set up with German femtosecond laser manufacturer 20/10 Perfect Vision. Under the terms of the agreement, B&L will acquire all outstanding and unowned shares of TPV for up to €450m ($622m), based on the achievement of certain milestones and earnouts. TPV was formed in 2009 to develop excimer and femtosecond laser technology for treating presbyopia and restoring the ability to accommodate and focus on near objects (www.clinica.co.uk, 1 May 2009). In March, B&L gained global distribution rights to a femtosecond laser for eye surgery developed by TVP for an undisclosed fee (www.clinica.co.uk, 28 March 2011). TPV has already filed a 510(k) application with the US FDA for the laser, and anticipates approval "in the coming months", a B+L spokesperson told Clinica. It also plans to CE mark the device for sale in Europe by the end of the year.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.